+

WO1999000401A1 - Oligonucleotides 3'-monophosphorylisants - Google Patents

Oligonucleotides 3'-monophosphorylisants Download PDF

Info

Publication number
WO1999000401A1
WO1999000401A1 PCT/CN1998/000102 CN9800102W WO9900401A1 WO 1999000401 A1 WO1999000401 A1 WO 1999000401A1 CN 9800102 W CN9800102 W CN 9800102W WO 9900401 A1 WO9900401 A1 WO 9900401A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
oligonucleotide
monophosphorylated
stability
cells
Prior art date
Application number
PCT/CN1998/000102
Other languages
English (en)
Chinese (zh)
Inventor
Chang-De Lu
Min Zhuang
Yu-Lei Xia
Original Assignee
Shanghai Institute Of Biochemistry, Chinese Academy Of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute Of Biochemistry, Chinese Academy Of Sciences filed Critical Shanghai Institute Of Biochemistry, Chinese Academy Of Sciences
Priority to AU79051/98A priority Critical patent/AU7905198A/en
Priority to JP50518799A priority patent/JP2002508768A/ja
Publication of WO1999000401A1 publication Critical patent/WO1999000401A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Definitions

  • the present invention relates to modified oligonucleotides, especially 3'-0H monophosphorylated modified oligonucleotides to increase stability and reduce toxic side effects.
  • the monophosphorylated modified oligonucleotides can be used as a treatment Drug. technical background
  • Oligonucleotides include antisense oligonucleotides, anti-gene oligonucleotides (also known as triple helix-forming oligonucleotides), etc., which can be used to suppress gene expression, and are a new therapeutic method developed in recent years Wagner, RW, Nature, 1994, 372, 333-335; Crook, ST, Annu. Rev. Pharmacol. Toxica l., 1992, 32, 329-376; Helene, C, Eur. J. Cancer, 1994, 30A, 1721-1726; Crooke, ST, Ant i sense Nucle ic ac ids Drug Dev., 1996, 6, 141-147).
  • Its mechanism of action includes blocking the replication, transcription, and translation of viral genes, as well as the transcription and translation of harmful genes in the human body, and the degradation of target RNA by the action of RNase H enzymes in the body. It is a class of highly specific and toxic side effects Small therapeutic drugs.
  • Antisense oligonucleotides currently in clinical trials include anti-HIV GEM91 (Phase II), anti-inflammatory ISIS2302 (Phase II), anti-cancer ISIS3521 (Phase I) and ISIS5132 (Phase I), anti-AIDS patients CMV retinitis ISIS2922 (Phase III), LR-3001 (Phase I) for the treatment of chronic myelogenous leukemia (Genet ic Engineer ing News, 1996, 16, 29-34).
  • the oligonucleotide fragments enter the human body, they are susceptible to degradation by the enzyme system in the human body, that is, the oligonucleotides entering the human body do not reach the target organ, and the target cells are degraded, so the expected therapeutic effect cannot be achieved (Hoke, GD, et a l. Nuc le ic Ac ids Res., 1991, 19, 5734-5748) 0 Therefore, it is very important to improve the stability of the oligonucleotide, especially its anti-enzymatic ability. In this way, not only can Increasing the efficacy and reducing the amount of medicine can also further reduce the cost of treatment and reduce side effects.
  • the object of the present invention is to provide a 3'-monophosphorylated oligonucleotide to increase the stability of the oligonucleotide and reduce the toxic and side effects.
  • 3'-phosphate solid phase column (3'-phosphate CPG Glen Research company product, full name 2_ [2- (4, 4, -dimethoxytriphenylmethoxy) ethanesulfonyl) ethyl] Succinyl long-chain alkylamine-microporous glass beads (2- [2- (4, 4,-Dimethoxy tri tyloxy) ethylsulfomyl] ethyl-succinoyl long chain alkylamino-CPG)), synthesized on ABI 391EP DNA synthesizer The 3'-monophosphorylated oligonucleotide was obtained by removing the protecting group through concentrated ammonia.
  • snake venom phosphodiesterase is used to represent the 3'-5 'exonuclease in the body
  • DNase I is used to represent the endonuclease in the body.
  • 3'-phosphorylated oligonucleotide fragments are resistant to snake venom phosphodiesterase, and the stability in serum and cells is significantly higher than that of 3 'unmodified or y-partial phosphorothioate-modified Nucleotide, slightly higher than phosphorothioate-modified oligonucleotide. Moreover, the 3'-phosphorylation modification does not affect the rate at which the oligonucleotide enters the cell, which is superior to the phosphorothioate-modified oligonucleotide.
  • 3'-monophosphorylated oligonucleotides can be degraded by 3'-5 'exonuclease only after the 3' phosphate is cut off by a phosphodiesterase.
  • the 3'-monophosphorylated oligonucleotide has high stability in serum and intracellular cells, indicating that the activity of phosphodiesterase in serum and intracellular cells is not high.
  • 3′-monophosphorylated oligonucleotide primers once bound to DNA, can also inhibit virus D replication or RNA reverse transcription.
  • Most of the currently used antisense oligonucleotides are phosphorothioate-modified, 3 ', 0H, oligonucleotides, which do not inhibit viral DM replication or RNA reverse transcription.
  • the 3'-monophosphorylated oligonucleotide has no effect on normal base pairing, and thus can ensure that the modified oligonucleotide is correctly and specifically paired with the target DNA or RM.
  • a 3'-monophosphorylated oligonucleotide fragment designed based on a specific sequence of DNA or RNA of a harmful gene such as a virus or a tumor gene can specifically bind to target DNA or RM to block the replication and transcription of viral DNA And translation, can also suppress the transcription and translation of harmful genes in the human body, and can also use RNaseH in the body to be 3'-monophosphorylated Oligonucleotide-bound target RNA is degraded. Therefore, due to the above-mentioned mechanism of action and superior properties, 3'-monophosphorylated oligonucleotides have more biological functions.
  • the 3'-monophosphorylated oligonucleotide provided by the present invention has the advantages of being more stable and easier to be taken up by cells than the phosphorothioate-modified oligonucleotide.
  • the phosphate group is an inherent component in natural nucleic acids, the use of the phosphate group as a modification group does not introduce non-natural modification components, and its metabolic degradation products do not have any toxic and side effects. Therefore, compared with other chemical modification methods It is safer to use and its overall performance is better than the most widely used thiophosphate-substituted oligonucleotides.
  • -Monophosphorylated oligonucleotides can specifically bind to target DM or RNA, and inhibit replication, transcription and translation of viral DNA. Therefore, 3'-monophosphorylated oligonucleotides are expected to become a clinically effective drug.
  • Article 1 y is an OH group
  • oligonucleotide 2 is a monophosphate group
  • the third oligonucleotide is connected through a phosphorothioate bond between all the nucleotides, and is a 0H group.
  • the third oligonucleotide of the fourth oligonucleotide has three phosphorophosphate diester bonds, and the rest are phosphorodiphosphates. Ester bond, 3 'is a 0H group.
  • Article 2 3'-monophosphorylated oligonucleotide uses 0.2 ⁇ ⁇ 3' phosphate solid phase column (3'-phosphate CPG Glen Research company product, full name 2 ⁇ [2- (4,4, —Dimethyltriphenylmethoxy) ethanesulfonyl] ethyl-succinyl long-chain alkylamine-microporous glass beads (2- [2- (4,4'- Dimethoxy trityloxy) ethylsulfomyl] ethyl-succinoyl long chain alkylamino-CPG)) was synthesized on a ABI 391EP DM synthesizer using a 0.2 mole synthesis sequence.
  • Oligonucleotides whose 3 ′ is 0H in Article 1 were synthesized using a 0.2 ⁇ dT solid-phase column (Glen Research product) using the same synthesis sequence.
  • Articles 3 and 4 were synthesized using a dA solid-phase column (Glen Research product), which was synthesized in the same synthetic sequence, and the sulfuric acid reagent was used instead of the oxidizing reagent at the position modified by thiophosphoric acid (see Iyer, RT, et al. J. Org Chem. 1990, 55, 4693-4699), the rest are the same.
  • the four oligonucleotide fragments (3'0H, 3'P, SP, 3SP) obtained in Example 1 were each using T4 Polynucleotide kinase (T4 ⁇ ) at its 5 'end with the 32 ⁇ , taking 50 pmol oligonucleotide fragment, add 50 ⁇ ⁇ [ ⁇ - 32 p ] -ATP, 2 units of T4 polynucleotide Kinase, 1 ⁇ 1 10-fold buffer, add double distilled water to 10 ⁇ 1, and incubate at 37 ° C for 1 hour.
  • T4 Polynucleotide kinase T4 Polynucleotide kinase
  • Example 2 the same sample labeled with 32 P to prepare four oligonucleotides, which were added in the non-labeled oligonucleotide to a final concentration of 5 ⁇ mol / L, DNase I was added to 100 U / ml, buffered The solution is 10-leg ol / L Tris-HCl, 5 mraol / L MgCl 2 , 0.1% BSA, pH 8. 0, 37 ° C, and maintained at 0, 0.5, 1, 1.5, 2, 4 Take 5 ⁇ l each at 1, 8, 12, and 24 hours. Add an equal volume of loading buffer and mix. Use 7 mol / L urea-20% polyacrylamide gel electrophoresis for identification.
  • Example 2-four kinds of 32 P-labeled oligonucleotides were prepared, and unlabeled oligos were respectively added thereto.
  • Nucleotide to a final concentration of 5 ⁇ / L add human serum to a final concentration of 40%, incubate at 37 ° C, and take 5 ⁇ l each at 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24 hours Add an equal volume of loading buffer and mix with 7 mol / L urea-20% polyacrylamide gel electrophoresis for identification.
  • Inoculate 2 x 10 5 HeLa cells in a 35mm petri dish add 1.5 ml of cell culture solution (DMEM contains 10% calf serum), and grow to 37%-60% of the area of the culture well at 37 ° C 5% C0 2 and aspirate.
  • DMEM contains 10% calf serum

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des oligonucléotides 3'-monophosphorylants dont la stabilité dans le sérum et dans les cellules est remarquablement supérieure à celle des oligonucléotides non modifiés et un peu supérieure à celle des oligonucléotides modifiés par un phosphorothioate. Ceci a été démontré par l'étude de ces nucléotides in vitro et dans les cellules. La capacité de ces nucléotides à être absorbés par les cellules est supérieure à celle des nucléotides non modifiés et des nucléotides modifiés par un phosphorothioate. Leurs produits de dégradation métabolique ne présentent aucune toxicité et pas d'effets secondaires, en raison du fait que les oligonucléotides 3'-monophosphorylants ne renferment pas d'éléments de modification non naturels. Par conséquence, lorsqu'ils sont utilisés comme agents thérapeutiques, les oligonucléotides 3'-monophosphorylants sont plus avantageux et plus sûrs que les oligonucléotides modifiés par un phosphorothioate.
PCT/CN1998/000102 1997-06-28 1998-06-26 Oligonucleotides 3'-monophosphorylisants WO1999000401A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU79051/98A AU7905198A (en) 1997-06-28 1998-06-26 3'-monophosphorylating oligonucleotides
JP50518799A JP2002508768A (ja) 1997-06-28 1998-06-26 ３’−モノリン酸化オリゴヌクレオチド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN97106495A CN1060177C (zh) 1997-06-28 1997-06-28 3′－单磷酸化寡核苷酸
CN97106495.4 1997-06-28

Publications (1)

Publication Number Publication Date
WO1999000401A1 true WO1999000401A1 (fr) 1999-01-07

Family

ID=5168733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN1998/000102 WO1999000401A1 (fr) 1997-06-28 1998-06-26 Oligonucleotides 3'-monophosphorylisants

Country Status (4)

Country Link
JP (1) JP2002508768A (fr)
CN (2) CN1060177C (fr)
AU (1) AU7905198A (fr)
WO (1) WO1999000401A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345163B2 (en) * 2002-08-28 2008-03-18 Quiatech Ab Process for separating and deprotecting oligonucleotides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028985A (ja) * 1983-07-27 1985-02-14 Takara Shuzo Co Ltd オリゴヌクレオチドの製造法
EP0266168A2 (fr) * 1986-10-31 1988-05-04 Amoco Corporation Compositions et méthodes de synthèse d'oligonucléotides dont l'extrémité 5' est phosphorylée
EP0464638A2 (fr) * 1990-07-02 1992-01-08 Hoechst Aktiengesellschaft Analogues d'oligonucléotides avec liaisons terminals 3'-3'-resp. 5'-5'-internucléotidiques
CN1098107A (zh) * 1993-01-29 1995-02-01 三共株式会社 改性寡脱氧核苷酸，它们的制备和其治疗用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028985A (ja) * 1983-07-27 1985-02-14 Takara Shuzo Co Ltd オリゴヌクレオチドの製造法
EP0266168A2 (fr) * 1986-10-31 1988-05-04 Amoco Corporation Compositions et méthodes de synthèse d'oligonucléotides dont l'extrémité 5' est phosphorylée
EP0464638A2 (fr) * 1990-07-02 1992-01-08 Hoechst Aktiengesellschaft Analogues d'oligonucléotides avec liaisons terminals 3'-3'-resp. 5'-5'-internucléotidiques
CN1098107A (zh) * 1993-01-29 1995-02-01 三共株式会社 改性寡脱氧核苷酸，它们的制备和其治疗用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROC. NATL. ACAD. SCI. U.S.A., Vol. 78, No. 10, Oct. 1981, pages 5993-5997. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345163B2 (en) * 2002-08-28 2008-03-18 Quiatech Ab Process for separating and deprotecting oligonucleotides

Also Published As

Publication number Publication date
CN1203919A (zh) 1999-01-06
CN1060177C (zh) 2001-01-03
JP2002508768A (ja) 2002-03-19
CN1261893A (zh) 2000-08-02
AU7905198A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
JP3529135B2 (ja) 特定のｒｎａ鎖の切断方法
US7495088B1 (en) Modified nucleotide compounds
US5532130A (en) Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
EP1470144B1 (fr) Oligonucleotides comportant des segments alternatifs et utilisations associees
AU709924B2 (en) Cross-linking oligonucleotides
US5286717A (en) Inhibitors for replication of retroviruses and for the expression of oncogene products
EP1113020B1 (fr) Nucléosides et oligonucléosides contenant des amas de bore
US20030144231A1 (en) Oligonucleotide analogues
AU2003202376A1 (en) Oligonucleotides comprising alternating segments and uses thereof
JPH02502516A (ja) 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
IL104461A (en) Oligonucleotide analogs, their preparation and pharmaceutical compositions containing them
JP3676388B2 (ja) 非ヌクレオチド基を有する３′−誘導されたオリゴヌクレオチド類似体、その製法および使用
US6033909A (en) Oligonucleotide analogs, their preparation and use
US6312953B1 (en) Bifunctional Crosslinking oligonucleotides adapted for linking to a target sequence of duplex DNA
WO1999000401A1 (fr) Oligonucleotides 3'-monophosphorylisants
EP0931090B1 (fr) Vecteurs oligonucleotidiques chimeres ameliores
KR100257972B1 (ko) 높은 키랄 순도의 포스포로티오에이트 결합기를 가지는 올리고뉴클레오티드
WO2001032924A1 (fr) Compositions, procedes de syntese et utilisation de nouvelles structures d'acides nucleiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98806676.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: (EXCEPT AL, AM, AT, AZ, BA, BB, BG, BR, BY, CU, CZ, DK, EE, ES, FI, GE, GH, GM, GW, HU, ID, IL, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AP (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), EA (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OA (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG))

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 79051/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1199901127

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 09446804

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载